A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer

• Published in: British journal of cancer 2024-04, Vol.130 (7), p.1149-1156
• Main Authors: Holt, Simon, Verrill, Mark, Pettit, Laura, Rigg, Anna, Hickish, Tamas, Archer, Caroline, Dent, Jo, Dillon, Marianne, Nathan, Mark, Barthelmes, Ludger, Rehman, Shazza, Sharaiha, Yousef, Innis, Paige, Sai-Giridhar, Priya, Khawaja, Saira
• Format: Article
• Language: English
• Subjects: 631/208/199; 631/67/69; 692/308/53/2423; 692/4017; 692/4028/67/1347; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer Research; Chemotherapy; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision making; Drug Resistance; Epidemiology; ErbB-2 protein; Female; Gene Expression Profiling; Hormones - therapeutic use; Humans; Lymph nodes; Molecular Medicine; Neoplasm Recurrence, Local - drug therapy; Oncology; Prospective Studies; State Medicine; United Kingdom
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-024-02588-9

Background For a tumour profiling test to be of value, it needs to demonstrate that it is changing clinical decisions, improving clinical confidence, and of economic benefit. This trial evaluated the use of the Oncotype DX Breast Recurrence Score® assay against these criteria in 680 women with hormone receptor-positive (HR+), HER2-negative early breast cancer with 1–3 lymph nodes positive (LN+) in the UK National Health Service (NHS). Methods Prior to receipt of the Recurrence Score (RS) result, both the physician and the patient were asked to state their preference for or against chemotherapy and their level of confidence on a scale of 1–5. Following receipt of the RS result, the physician and patient were asked to make a final decision regarding chemotherapy and record their post-test level of confidence. Results Receipt of the RS result led to a 51.5% (95% CI, 47.2–55.8%) reduction in chemotherapy, significantly increased the relative and absolute confidence for both physicians and patients and led to an estimated saving to the NHS of £787 per patient. Conclusion The use of the Oncotype DX assay fulfils the criteria of changing clinical decisions, improving confidence and saving money.